09 August 2017
Visiongain has launched a new pharma report Global Infectious Disease Diagnostics Market Forecast 2017-2027: Revenue Prospects by Disease Type (HIV/AIDS, Hepatitis, Tuberculosis, Malaria, Chlamydia), Technique (Immunoassay, Molecular Diagnostics, POC/Rapid Diagnosis, Microbiology), End User (Hospitals, Clinical Laboratories, Others) and Geography
Infectious diseases such as HIV, Hepatitis, Malaria and Tuberculosis are some of the major causes of disease burden in the world. Large numbers of people across the globe in both developed and developing nations are suffering from one or more infectious diseases and more and more people are expected to be added to the patient pool in coming years. For many diseases, if the condition is not diagnosed in a timely manner, this can lead to serve illness and can be fatal.
Highly infectious diseases have the potential to lead to mass mortality as have been seen in historical examples of disease epidemics. To treat these dangerous diseases before they are transmitted, faster and more reliable testing techniques are needed. Although today we can already see many examples of rapid diagnostics, there are many situations in which a diagnostic test can take days if not weeks to return a result. This kind of delay could lead to inferior patient outcomes than if the disease were to be identified and treated in the most rapid manner. Hence, in order to help contain these diseases, fast and accurate diagnosis is required which can ensure timely treatment.
The lead Visiongain report analyst for this report commented; “Infectious Disease Diagnostics are used in the process of identifying disease causing foreign organisms in the body by using different types of techniques. Infectious diseases are some of the most common types of diseases across the globe and their prevalence in developed and developing countries is increasing. As a result, more and more people are becoming aware about the various diseases and improvements in diagnostic techniques are helping us to identify and diagnose diseases at earlier stages than ever before.
As physicians prefer evidence based treatment, the Infectious Disease Diagnostics market is likely to increase more in the forecast years, as these diagnostics aid in making treatment decisions. Several government-funded programs all over the globe are increasingly providing free screening and tests in order to increase awareness, accurately diagnose diseases, and minimize the chances of infection. Such initiatives are anticipated to boost the market growth in the next few years. Emerging markets such as the BRIC markets are expected to be the biggest contributor in the growth of Infectious Disease Diagnostics market as increase in income levels, better access to diagnosis will contribute to market growth. However developed nations such as United States and EU5 nations will continue to dominate the market in terms of revenue.”
The Infectious Disease Diagnostics market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the Infectious Disease Diagnostics market include Abbott Laboratories, Becton, Dickinson and Company, Biomérieux, Bio-Rad Laboratories, Alere, Inc., Siemens Healthcare, Roche Diagnostics, Danaher Corporation and Thermo-Fisher Scientific, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.